The Efficacy of Everolimus and Sunitinib in Patients with Sporadic or Germline Mutated Metastatic Pancreatic Neuroendocrine Tumors

被引：0
|
作者：
Nunez, J. E. [1 ]
Donadio, M. [2 ]
Rocha Filho, D. [3 ]
Rego, J. [4 ]
Barros, M. [2 ]
Formiga, M. N. [2 ]
Lopez, R. [5 ]
Riechelmann, R. [2 ]
机构：
[1] AC Camargo Canc Ctr, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
[2] AC Camargo Canc Ctr, Sao Paulo, Brazil
[3] Hosp Univ Walter Cantidio, Fortaleza, Ceara, Brazil
[4] Hosp Univ Onofre Lopes, Natal, RN, Brazil
[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
来源：
NEUROENDOCRINOLOGY | 2019年 / 108卷
关键词：
neuroendocrine; pancreatic net; metastatic net; everolimus; sunitinib; men1; multiple endocrine neoplasia type 1; vhl; von-hippel-lindau; germline mutation; sporadic;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I11
引用
收藏
页码：176 / 176
页数：1
相关论文
共 50 条
  • [1] The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors
    Nunez, Jose Eduardo
    Donadio, Mauro
    Rocha Filho, Duilio
    Rego, Juliana Florinda
    Barros, Milton
    Formiga, Maria Nirvana
    Lopez, Rossana
    Riechelmann, Rachel
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (04) : 645 - 651
  • [2] Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors
    Wiedmann, Marcus W.
    Mossner, Joachim
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6 : 381 - 393
  • [3] Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors
    Liakakos, Theodore
    Roukos, Dimitrios H.
    FUTURE ONCOLOGY, 2011, 7 (09) : 1025 - 1029
  • [4] Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumors Resistant to Prior Treatments
    Angelousi, A.
    Kampel, K.
    O'Toole, D.
    Kaltsatoy, M.
    Boutzios, G.
    Alexandraki, K.
    Kaltsas, G.
    De Herder, W.
    NEUROENDOCRINOLOGY, 2016, 103 : 77 - 77
  • [5] Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor
    Changhoon Yoo
    Hyungwoo Cho
    Min Jeong Song
    Seung-Mo Hong
    Kyu-pyo Kim
    Heung-Moon Chang
    Heejung Chae
    Tae Won Kim
    Yong Sang Hong
    Min-Hee Ryu
    Yoon-Koo Kang
    Song Cheol Kim
    Baek-Yeol Ryoo
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 139 - 146
  • [6] Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor
    Yoo, Changhoon
    Cho, Hyungwoo
    Song, Min Jeong
    Hong, Seung-Mo
    Kim, Kyu-pyo
    Chang, Heung-Moon
    Chae, Heejung
    Kim, Tae Won
    Hong, Yong Sang
    Ryu, Min-Hee
    Kang, Yoon-Koo
    Kim, Song Cheol
    Ryoo, Baek-Yeol
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 139 - 146
  • [7] Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison
    Signorovitch J.
    Swallow E.
    Kantor E.
    Wang X.
    Klimovsky J.
    Haas T.
    Devine B.
    Metrakos P.
    Experimental Hematology & Oncology, 2 (1)
  • [8] Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
    Ambrosio, M. R.
    Guerra, A.
    Lupo, S.
    Bondanelli, M.
    Sartori, S.
    Pansini, G.
    Degli Uberti, E.
    Zatelli, M. C.
    NEUROENDOCRINOLOGY, 2012, 96 : 17 - 18
  • [9] Role of everolimus in pancreatic neuroendocrine tumors
    Goldstein, Robert
    Meyer, Tim
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (11) : 1653 - 1665
  • [10] Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data
    Valle, Juan W.
    Borbath, Ivan
    Rosbrook, Brad
    Fernandez, Kathrine
    Raymond, Eric
    FUTURE ONCOLOGY, 2019, 15 (11) : 1219 - 1230
12345